HR
ABBV icon

Howe & Rusling’s AbbVie ABBV Stock Holding History

Howe & Rusling’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19M Buy
87,347
+1,207
+1% +$268K 1.24% 22
2025
Q4 		$19.7M Sell
86,140
-3,628
-4% -$826K 1.3% 22
2025
Q3 		$20.8M Buy
89,768
+3,403
+4% +$693K 1.43% 16
2025
Q2 		$16M Buy
86,365
+2,957
+4% +$550K 1.18% 22
2025
Q1 		$17.5M Sell
83,408
-239
-0.3% -$46.5K 1.47% 18
2024
Q4 		$14.9M Buy
83,647
+10,370
+14% +$1.91M 1.28% 19
2024
Q3 		$14.5M Buy
73,277
+10,205
+16% +$1.9M 1.24% 21
2024
Q2 		$10.8M Buy
63,072
+2,356
+4% +$390K 0.99% 32
2024
Q1 		$11.1M Buy
60,716
+3,183
+6% +$549K 1.06% 29
2023
Q4 		$8.92M Sell
57,533
-1,250
-2% -$182K 0.95% 36
2023
Q3 		$8.76M Buy
58,783
+56,528
+2,507% +$8.3M 1.03% 33
2023
Q2 		$304K Buy
2,255
+50
+2% +$7.33K 0.03% 179
2023
Q1 		$351K Sell
2,205
-233
-10% -$35.6K 0.04% 162
2022
Q4 		$394K Sell
2,438
-589
-19% -$90.3K 0.05% 140
2022
Q3 		$406K Buy
3,027
+515
+21% +$73.9K 0.05% 140
2022
Q2 		$385K Buy
2,512
+498
+25% +$76.1K 0.05% 140
2022
Q1 		$326K Sell
2,014
-113
-5% -$16.4K 0.04% 154
2021
Q4 		$288K Sell
2,127
-1
-0% -$118 0.03% 173
2021
Q3 		$230K Buy
2,128
+15
+0.7% +$1.71K 0.03% 183
2021
Q2 		$238K Buy
2,113
+84
+4% +$9.46K 0.03% 168
2021
Q1 		$220K Sell
2,029
-78
-4% -$8.34K 0.03% 163
2020
Q4 		$226K Buy
2,107
+322
+18% +$30.9K 0.03% 155
2020
Q3 		$156K Hold
1,785
– – 0.03% 168
2020
Q2 		$175K Buy
1,785
+425
+31% +$37.4K 0.03% 149
2020
Q1 		$104K Sell
1,360
-150
-10% -$12.8K 0.02% 191
2019
Q4 		$134K Sell
1,510
-12,055
-89% -$1M 0.02% 210
2019
Q3 		$1.03M Buy
13,565
+79
+0.6% +$5.42K 0.18% 97
2019
Q2 		$981K Sell
13,486
-3,148
-19% -$247K 0.17% 97
2019
Q1 		$1.34M Sell
16,634
-391
-2% -$32K 0.23% 83
2018
Q4 		$1.57M Buy
17,025
+167
+1% +$14.7K 0.33% 64
2018
Q3 		$1.59M Sell
16,858
-882
-5% -$83.6K 0.27% 67
2018
Q2 		$1.64M Sell
17,740
-11,153
-39% -$1.09M 0.3% 65
2018
Q1 		$2.73M Sell
28,893
-85,826
-75% -$9.43M 0.5% 61
2017
Q4 		$11.1M Sell
114,719
-4,829
-4% -$455K 2.02% 10
2017
Q3 		$10.6M Sell
119,548
-9,212
-7% -$701K 1.97% 10
2017
Q2 		$9.34M Buy
128,760
+4,459
+4% +$300K 1.9% 13
2017
Q1 		$8.1M Buy
124,301
+2,601
+2% +$164K 1.62% 16
2016
Q4 		$7.62M Sell
121,700
-260
-0.2% -$15.9K 1.67% 14
2016
Q3 		$7.69M Buy
121,960
+9,743
+9% +$631K 1.66% 12
2016
Q2 		$6.95M Buy
112,217
+14,132
+14% +$861K 1.53% 16
2016
Q1 		$5.6M Buy
98,085
+12,691
+15% +$707K 1.26% 28
2015
Q4 		$5.06M Sell
85,394
-1,244
-1% -$71.7K 1.16% 37
2015
Q3 		$4.71M Buy
86,638
+2,661
+3% +$173K 1.17% 38
2015
Q2 		$5.64M Buy
83,977
+10,411
+14% +$680K 1.23% 29
2015
Q1 		$4.31M Buy
73,566
+49,665
+208% +$3M 0.97% 43
2014
Q4 		$1.56M Sell
23,901
-610
-2% -$38.5K 0.38% 68
2014
Q3 		$1.42M Buy
24,511
+24,011
+4,802% +$1.33M 0.33% 72
2014
Q2 		$28K Sell
500
-26,131
-98% -$1.37M 0.01% 345
2014
Q1 		$1.37M Buy
26,631
+26,131
+5,226% +$1.32M 0.34% 63
2013
Q4 		$26K Sell
500
-25,708
-98% -$1.26M 0.01% 364
2013
Q3 		$1.16M Sell
26,208
-3,079
-11% -$136K 0.42% 64
2013
Q2 		$1.21M Buy
+29,287
New +$1.28M 0.34% 64

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Howe & Rusling's ABBV Position: Q1 2026 in Review

Howe & Rusling increased its AbbVie (ABBV) stake by 1.4% in Q1 2026, buying an estimated $268K and bringing the position to 87,347 shares worth $19M. The position accounts for 1.24% of the portfolio, ranked #22.

Howe & Rusling first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $20.8M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Howe & Rusling held 87,347 shares of AbbVie worth $19M as of Q1 2026.
  • Howe & Rusling bought 1,207 AbbVie shares in Q1 2026, an estimated $268K.
  • AbbVie made up 1.24% of Howe & Rusling's portfolio in Q1 2026, its #22 holding.
  • Howe & Rusling first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Howe & Rusling's AbbVie position peaked at $20.8M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Howe & Rusling's 13F filing for Q1 2026, filed 28 Apr 2026.